Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D07YEK
|
||||
| Former ID |
DCL000181
|
||||
| Drug Name |
NV-52
|
||||
| Indication | Inflammatory bowel disease [ICD9: 555, 556; ICD10:K50, K51] | Phase 1 | [1] | ||
| Company |
Novogen
|
||||
| Target and Pathway | |||||
| Target(s) | Thromboxane-A synthase | Target Info | Inhibitor | [2], [3] | |
| BioCyc Pathway | C20 prostanoid biosynthesis | ||||
| KEGG Pathway | Arachidonic acid metabolism | ||||
| Metabolic pathways | |||||
| Platelet activation | |||||
| PathWhiz Pathway | Arachidonic Acid Metabolism | ||||
| WikiPathways | Prostaglandin Synthesis and Regulation | ||||
| Arachidonic acid metabolism | |||||
| Phase 1 - Functionalization of compounds | |||||
| Eicosanoid Synthesis | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800017139) | ||||
| REF 2 | Nv-52: a novel thromboxane synthase inhibitor for the treatment of inflammatory bowel disease. Expert Opin Investig Drugs. 2007 Aug;16(8):1255-66. | ||||
| REF 3 | Phase Ib single- and multiple-dose pharmacokinetic study of oral NV-52 in healthy volunteers. Drugs R D. 2008;9(3):159-66. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.